PF-670462

PF-670462 is a potent, selective, and ATP-competitive small molecule inhibitor of Casein Kinase 1 delta (CK1δ) and Casein Kinase 1 epsilon (CK1ε). Developed by Pfizer, the compound has been extensively used as a pharmacological tool to study the regulation of the circadian clock, as CK1δ and CK1ε are critical for the phosphorylation and subsequent degradation of Period (PER) proteins. In preclinical models, administration of PF-670462 has been shown to induce significant phase delays in circadian rhythms. While primarily investigated for sleep and circadian rhythm disorders, it has also been evaluated in other therapeutic areas including oncology (such as glioblastoma) and neurodegenerative diseases, though it often serves as a reference compound rather than a clinical candidate in recent literature.

Other names

4-[1-cyclohexyl-4-(4-fluorophenyl)-1H-imidazol-5-yl]-2-pyrimidinamine